title: Pembrolizumab for treatment of refractory melanoma.
authors.forename: Sanjeet
authors.initials: S
authors.lastname: Bagcchi
mesh_terms: D006801:Humans; D008297:Male; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D016001:Confidence Intervals; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D008545:Melanoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C582435:pembrolizumab